Business Wire

CA-GLOBALLOGIC-INC.

19.10.2020 08:02:06 CEST | Business Wire | Press release

Share
GlobalLogic Appoints Industry Veteran Rajaram Radhakrishnan as Chief Revenue Officer

GlobalLogic Inc. , a leader in Digital Product Engineering, announced that Rajaram (Raj) Radhakrishnan has joined the company as Chief Revenue Officer. Mr. Radhakrishnan will be responsible for the strategy and execution of GlobalLogic’s unified go-to-market to drive the company’s next growth phase. The decision to introduce the CRO role comes as GlobalLogic continues to exceed current business goals and seeks to maintain that trajectory as it approaches the billion-dollar revenue mark and beyond. Raj will be responsible for all market-facing functions including Branding, Marketing, Sales, Channel and Strategic Partnerships.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201018005050/en/

“GlobalLogic’s success has been the result of a combination of sound business strategy and accelerating market demand for Digital Product Engineering services. We’ve rolled out valuable offerings for key industries, conducted strategic acquisitions, and delivered our services with a focus on customer delight for the marquee brands we serve,” said Shashank Samant, CEO, GlobalLogic. “Raj’s track record is impeccable. His experience is directly relevant to our business. We’re honored to have him on our team, and know his style of leadership and his customer orientation will ignite our next stage of growth.”

Before joining GlobalLogic, Raj was part of the Executive Leadership Team at Cognizant, serving as Senior Vice President and Global Head of Manufacturing, Logistics, Energy, and Utilities. Under his leadership, this business gained momentum across multiple new business segments and experienced tremendous growth and profitability—going on to become one of the most successful verticals at Cognizant. Prior to Cognizant, he held senior client relationship roles at Keane, Covansys and TCS. Mr. Radhakrishnan has lived and worked in multiple global geographies including Asia, Europe and North America.

“The need for smarter, more customer-centric digital products and experiences is massive, and GlobalLogic is extremely well positioned to service this need on a global scale,” said Mr. Radhakrishnan. “I’m excited to join the company with its talented management and employees and forward-leaning culture, and I look forward to contributing to the next chapter of GlobalLogic’s growth journey.”

Raj holds an M.B.A. from The Business School, London. He also holds an M.S. in Software Systems and a B.E. in Electronics and Communication Engineering from Birla Institute of Technology and Science and Anna University respectively.

Useful Links

GlobalLogic: http://www.globallogic.com
LinkedIn: https://www.linkedin.com/company/globallogic/
Facebook: https://www.facebook.com/GlobalLogic/
Twitter: https://twitter.com/GlobalLogic

About GlobalLogic

GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help our clients design and build innovative products, platforms, and digital experiences for the modern world. By integrating strategic design, complex engineering, and vertical industry expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the communications, financial services, automotive, healthcare, technology, media and entertainment, manufacturing, and semiconductor industries.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/GlobalLogic/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye